New York, NY (PRWEB) December 04, 2013
The medication safety advocates at DrugNews.net are announcing a new resource center for parents of children who have taken the antipsychotic drug Risperdal. The site will contain the latest research and safety warnings as well as updated legal news from lawsuits alleging side effects*.
DrugNews is a free resource designed to share the latest safety alerts, recalls, studies and legal news with those taking popular prescription drugs. Patients can avoid potential dangers, see if others are experiencing similar side effects and decide if they need legal advice.
Risperdal is an atypical antipsychotic drug approved to treat schizophrenia, bipolar disorder and autism in adults. However, Johnson & Johnson recently paid $2.2 billion in fines and pled guilty to allegations of promoting it for unapproved uses, such as treating ADHD in children**.
The DrugNews Risperdal Center has added studies linking the drug to alleged gynecomastia, or abnormal breast growth that can be accompanied by milk production***. A recent study also found antipsychotic drugs like Abilify, Risperdal, Seroquel and Zyprexa may allegedly triple the risk of type-2 diabetes in children****.
Parents have already filed lawsuits alleging Risperdal caused abnormal breast growth in children, leading to settlements by Johnson & Johnson*.
Anyone affected by alleged abnormal breast growth or diabetes after taking Risperdal is urged to visit DrugNews.net or speak with a lawyer about their legal options. Due to the specialized nature of these cases, DrugNews only recommends lawyers who have already handled Risperdal lawsuits.
Visit http://www.DrugNews.net today for more information on the research, side effects and litigation news related to Risperdal and other antipsychotic drugs, or to speak with a lawyer.
*Bloomberg, 9/10/12; bloomberg.com/news/2012-09-10/j-j-settles-risperdal-lawsuit-on-opening-day-of-trial.html; Banks v. Janssen Pharmaceuticals, Philadelphia Court of Common Pleas, January Term 2010, No. 00618
**Reuters, 11/4/13; reuters.com/article/2013/11/04/us-jnj-settlement-idUSBRE9A30MM20131104
***Cedars-Sinai Division of Endocrinology, Sept. 2012; ncbi.nlm.nih.gov/pubmed/22862307
****Vanderbilt University Medical Center, 8/22/13; news.vanderbilt.edu/2013/08/antipsychotic-drug-use-in-children-for-moodbehavior-disorders-increases-type-2-diabetes-risk/